XENE
Xenon Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$39.75
−30.69%Sep 17, 2026, 20:38 UTC
Xenon Pharmaceuticals temporarily paused enrollment of new patients in its clinical studies of an experimental drug for major depression and bipolar disorder following reports of mental and nervous system-related side effects.
Sep 17, 2026, 20:01 UTC
Xenon Pharmaceuticals submitted a New Drug Application to the U.S. Food and Drug Administration for azetukalner for the treatment of focal seizures.
Aug 25, 2026, 07:55 UTC
BlackRock Inc. acquired a new minority stake in Xenon Pharmaceuticals Inc., buying 7,522,482 shares valued at approximately $454.06 million, representing about 7.78% ownership, as disclosed in a 13F filing.
Source:Aug 7, 2026, 05:24 UTC
Xenon Pharmaceuticals Inc. held its Q2 2026 earnings call on August 6, 2026.
Source: